Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Department of Graduate School, Dalian Medical University, Dalian, China.
Urol Int. 2023;107(1):46-57. doi: 10.1159/000518562. Epub 2021 Oct 14.
This study aimed to compare the survival outcomes between trimodal therapy (TT) and partial cystectomy (PC) in muscle-invasive bladder cancer (MIBC) patients.
The data of 13,096 patients with MIBC diagnosed between 2004 and 2015 were retrieved from the Surveillance, Epidemiology, and End Results database. Among them, 4,041 patients underwent TT and 1,670 patients underwent PC. Propensity score matching was performed to balance the characteristics between the 2 treatment groups. A multivariate Cox regression analysis model and a competing risk model were used to evaluate overall survival (OS) and cancer-specific survival. Cumulative incidence survival curves were obtained using the Kaplan-Meier method.
Results of multivariate Cox analysis before propensity score matching showed that the TT group had a 31% reduction in cause-specific survival relative to the PC group (HR: 0.69, 95% CI: 0.61-0.78, p < 0.001) and a 28% reduction in OS (HR: 0.72, 95% CI: 0.66-0.79, p < 0.001). After propensity score matching, the 2 groups yielded 972 patients, with 3-year cause-specific survival rates of 54.1% and 68.5% in the TT group and the PC group, respectively.
Patients who underwent PC had a better prognosis than those who received TT. In addition, for MIBC patients who required bladder-sparing therapy, advanced age (≥80 years), pathological type of squamous cell carcinoma, and tumor stage of T3-4, N2-3, and M1 were independent poor prognostic factors.
本研究旨在比较三联疗法(TT)和部分膀胱切除术(PC)治疗肌层浸润性膀胱癌(MIBC)患者的生存结局。
从监测、流行病学和最终结果数据库中检索了 2004 年至 2015 年间诊断为 MIBC 的 13096 例患者的数据。其中,4041 例患者接受 TT 治疗,1670 例患者接受 PC 治疗。采用倾向评分匹配法平衡两组患者的特征。采用多变量 Cox 回归分析模型和竞争风险模型评估总生存期(OS)和癌症特异性生存期。采用 Kaplan-Meier 方法获得累积发生率生存曲线。
倾向评分匹配前的多变量 Cox 分析结果显示,TT 组的癌特异性生存率相对 PC 组降低了 31%(HR:0.69,95%CI:0.61-0.78,p<0.001),OS 降低了 28%(HR:0.72,95%CI:0.66-0.79,p<0.001)。经过倾向评分匹配后,两组各有 972 例患者,TT 组和 PC 组的 3 年癌特异性生存率分别为 54.1%和 68.5%。
接受 PC 治疗的患者预后优于接受 TT 治疗的患者。此外,对于需要保膀胱治疗的 MIBC 患者,高龄(≥80 岁)、病理类型为鳞状细胞癌以及肿瘤分期为 T3-4、N2-3、M1 是独立的不良预后因素。